A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

July 31, 2013

Conditions
Cancer, Metastatic
Interventions
DRUG

Carboplatin

Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.

DRUG

Pazopanib

Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.

Trial Locations (1)

87131-0001

University of New Mexico Cancer Center, Albuquerque

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

New Mexico Cancer Research Alliance

OTHER

NCT01542047 - A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter